Clinical Trials Browser

Phase 1/2 × Lung Neoplasms × tanespimycin × Clear all

NCT00431015 2012-12-10

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms